You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK)公佈Bcl-2抑制劑APG-2575治療中國復發╱ 難治性非霍奇金淋巴瘤患者的積極臨牀數據
格隆匯 06-13 07:32

格隆匯6月13日丨亞盛醫藥-B(06855.HK)發佈公吿,公司在2022年歐洲血液學協會年會(EHA 2022)上公佈了在研原創1類新藥Bcl-2選擇性抑制劑APG-2575治療中國復發╱難治性非霍奇金淋巴瘤(r/r NHLs)患者的I期臨牀試驗數據。

作為歐洲血液學領域規模最大的國際會議,EHA年會每年都有來自全球100多個國家的10,000餘名臨牀專業人士及研究員與會,共同分享並探討有關血液學的創新理念及最新的科學和臨牀研究成果。

APG-2575是亞盛醫藥自主研發的Bcl-2選擇性小分子抑制劑,通過選擇性抑制 Bcl-2蛋白來恢復腫瘤細胞程序性死亡機制(細胞凋亡),從而誘導腫瘤細胞凋亡,達到治療腫瘤的目的。APG-2575也是全球第二、國內首個進入關鍵註冊臨牀階段且具有明確療效的Bcl-2選擇性抑制劑,正在全球範圍內開展涉及多個血液腫瘤和實體瘤適應症的臨牀試驗,呈現巨大的臨牀開發潛力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account